Association between transforming growth factor β1 gene polymorphisms and IgA nephropathy

Journal of Nephrology

Volumn 17, Issue 6, 2004, Pages 786-793

  Carturan, Sonia ^a   Roccatello, Dario ^a   Menegatti, Elisa ^a   Di Simone, Debora ^a   Davit, Annalisa ^a   Piazza, Alberto ^a   Sena, Luigi Massimino ^a   Matullo, Giuseppe ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Institute for Scienctific Interchange Foundation   (Italy)

Author keywords

Gene polymorphism; IgA nephropathy; PCR RFLP; Transforming growth factor 1

Indexed keywords

ALANINE; CYSTEINE; GENOMIC DNA; GLYCINE; LEUCINE; PROLINE; THREONINE; TRANSFORMING GROWTH FACTOR BETA1; ADENINE; GUANINE; TGFB1 PROTEIN, HUMAN; THYMINE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE CONSTRUCT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; CASE CONTROL STUDY; DISEASE COURSE; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADENINE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; GUANINE; HAPLOTYPES; HUMANS; LEUCINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROLINE; THYMINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 16644365540     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Böttinger EP, Bitter M. TGF-β signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-10
2. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14: 681-5.
3. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor β complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316: 701-5.
4. Ward PA, Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998; 157 (suppl 4): S123-9.
5. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597-601.
6. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakeield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995; 92: 2572-6.
7. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta. Nature 1990; 346: 371-4.
8. Isaka Y, Beers DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-23.
9. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148-55.
10. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, Imai E. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999; 55: 465-75.
11. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, Hori M. Transforming growth factor-β1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 2000; 58: 1885-92.
12. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y. Transforming growth factor-β1 stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989; 159: 1435-40.
13. Border WA, Noble NA. Interactions of transforming growth factor-β1 and angiotensin II in renal fibrosis. Hypertens 1998; 31: 181-8.
14. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-9.
15. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 1999; 8: 93-7.
16. Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, Piccoli G, Sena LM. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15: 833-5.
17. Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC, Francis SE. Gunn J, Jeffery S, Heathcote K. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Lond) 1998; 95: 659-67.
18. Dempster A, Laird N, Rubin D. Maximum likelihood estimation from incomplete data via the EM algorithm. J Roy Statist Soc 1977; 39: 1-38.
19. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 245: 709-27.
20. Nussenzveig I, Saldanha LB, Marcondes M. Primary mesangial IgA nephropathy in Sao Paulo, Brasil. Nephron 1989; 52: 198-9.
21. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995; 100: 470-4.
22. Roccatello D, Picciotto G, Torchio M. Removal system of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest 1993; 69: 714-23.
23. Niemir ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, Walherr R. PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis. Kidney Int 1995; 48: 1530-41.
24. Lai KN, Tang SC, Guh J-Y, Chuang T-D, Lam MF, Chan LY, Tsang AW, Leung JC. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-β synthesis and signal transduction in human mesangial cells via the renin angiotensin system. J Am Soc Nephrol 2003; 14: 3127-37.
25. Peters H, Noble NA, Border WA. Transforming growth factor-beta in human glomerular injury. Curr Opin Nephrol Hypertens 1997; 6: 389-93.
26. Galla JH. IgA nephropathy. Kidney Int 1995; 47: 377-87.
27. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18: 12-9.
28. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207.
29. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal diseases, and a review of the literature. Medicine (Baltimore) 1994; 73: 79-102.
30. Schmidt S, Stier E, Hartung R, Stein G, Bahnisch J, Woodroffe A, Clarkson AR, Ponticelli C, Campise M, Mayer G, Ganten D, Ritz E. No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995; 26: 727-31.
31. Stratta P, Canavese C, Ciccone G, Barolo S, Dall'Omo AM, Fasano ME, Mazzola G, Berutti S, Fop F, Curtoni ES, Piccoli G. Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an Italian population. Am J Kidney Dis 1999; 33: 1071-9.
32. Menegatti E, Nardacchione A, Alpa M, Agnes C, Rossi D, Chiara M, Modena V, Sena LM, Roccatello D. Polymorphism of the uteroglobin gene in systemic lupus erythematosus and IgA nephropathy. Lab Invest 2002; 82: 543-6.
33. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
34. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis: possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990; 86: 453-62.
35. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M. TGF-β1 in glomerulosclerosis and intestinal fibrosis of adriamycin nephropathy. Kidney Int 1994; 45: 525-36.
36. Uboldi de Capei MU, Dametto E, Fasano ME, Rendine S, Curtoni ES. Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. Eur J Immunogenet 2003; 30: 5-10.
37. Cox ED, Hoffmann SC, Dimercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72: 720-6.
38. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 1998; 6: 193-7.
39. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 2003; 32: 297-310.
40. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC. A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003; 63: 2610-5.
41. Brezzi B, Brugnara M, Lupo A, Magistroni R, Furci L, Ligabue G, Bernich P, Turco A, Gomez-Lira M, Del Prete D, Maschio G. Genetic polymorphisms of TGFbeta1 and histological damage in IgA nephropathy. J Am Soc Nephrol 2002; 13: 131A.
42. Brezzi B, Lupo A, Brugnara M, Ligabue G, Magistroni R, Marcantoni C, Gomez-Lira M, Gambaro G, Turco A, Poli A, Maschio G. TGFbeta1 COD10 polymorphism is associated with progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 130A.
43. 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int 2003; 63: 1831-5.
44. Akai Y, Sato H, Ozaki H, Iwano M, Dohi Y, Kanauchi M. Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am J Kidney Dis 2001; 38 (suppl 1): S182-5.
45. Guo Z, Binswanger U, Knoflach A. Role of codon 10 and codon 25 polymorphisms on TGF-beta 1 gene expression and protein synthesis in stable renal allograft recipients. Transplant Proc 2002; 34: 2904-6.
46. Melk A, Henne T, Kollmar T, Strehlau J, Latta K, Offner G, Jhangri GS, Ehrich JH, Von Schnakenburg C. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. Kidney Int 2003; 64: 314-20.
47. McDaniel DO, Barber WH, Nguyan C, Rhodes SW, May WL, McDaniel LS, Vig PJ, Jemeson LL, Butkus DE. Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. Transpl Immunol 2003; 11: 107-11.
48. Lacha J, Hubacek JA, Potmesil P, Viklicky O, Malek I, Vitko S. TGF-beta I gene polymorphism in heart transplant recipients - effect on renal function. Ann Transplant 2001; 6: 39-43.
49. Baan CC, Balk AH, Holweg CT, Van Riemsdijk IC, Maat LP, Vantrimpont PJ, Niesters HG, Weimar W. Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant 2000; 19: 866-72.
50. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-7.
51. Hoffmann SC, Stanley EM, Cox ED, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 1444-50.
52. Cotton SA, Gbadegesin RA, Williams S, Brenchley PE, Webb NJ. Role of TGF-beta1 in renal parenchymal scarring following childhood urinary tract infection. Kidney Int 2002; 61: 61-72.
53. Hinke V, Seck T, Clanget C, Scheidt-Nave C, Ziegler R, Pfeilschifter J. Association of transforming growth factor-beta1 (TGFbeta1) T29 → C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta1 in a population-based sample of postmenopausal German women. Calcif Tissue Int 2001; 69: 315-20.
54. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-20.
55. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND. Spector TD. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93-7.